News
-
Savara Pharmaceuticals is seeking a high energy individual to fill a laboratory-based role in its formulation and analytical development laboratories. The successful candidate should be comfortable working in a start-up company and have experience supporting… Read more . . .
-
3M Drug Delivery Systems Division partners with pharmaceutical and biotech companies to develop pharmaceuticals using 3M’s inhalation or transdermal drug delivery technology. 3M offers a full range of feasibility, development and manufacturing capabilities combined with regulatory… Read more . . .
-
We are seeking a highly motivated, experienced scientist to join the Pharmaceutical Development group at our early-stage pharmaceutical company to provide technical leadership and hands-on performance. The ideal candidate will have expertise in dry powder… Read more . . .
-
An innovative, inhalation-focused development organisation with multiple UK sites is now looking for an Analytical Development Manager at their modern facility in the southwest of the UK. The successful candidate will lead an experienced team… Read more . . .
-
The laboratory groups at Catalent RTP are responsible for the support of pharmaceutical product development in a range of dosage forms both directly with customers and in collaboration with other Catalent facilities. This includes formulation… Read more . . .
-
The laboratory groups at Catalent RTP are responsible for the support of pharmaceutical product development in a range of dosage forms both directly with customers and in collaboration with other Catalent facilities. This includes formulation… Read more . . .
-
Numerous studies have described the difficulties patients experience in using metered dose inhalers (MDIs), including a recent article in the Journal of General Internal Medicine (JGIM) that found 86% of hospitalized patients enrolled in a… Read more . . .
-
Chuck Bramlage has been appointed President and Chief Executive Officer of Pearl Therapeutics, replacing interim President and CEO Howard Rosen. Pearl, a California pharmaceutical company developing inhaled treatments for COPD and asthma, was founded in… Read more . . .
-
On the second day of the Drug Delivery to the Lungs meeting in December 2010 (DDL 21), Xiang Kou, a grad student from the National University of Singapore who had been spending time as a… Read more . . .
-
The Impactor Sub-Team of the European Pharmaceutical Aerosol Group (EPAG), a consortium of pharmaceutical companies that develop pulmonary and intranasal drugs, has focused its attention on the potential benefits of the abbreviated impactor method (AIM),… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden